Last Updated: Dec 10, 2021

On December 8, BioNTech and Pfizer (PFE.N) said a three-shot course of their COVID-19 vaccine was able to neutralise the new Omicron variant in a laboratory test, an early signal that booster shots could be key to protection against infection from the newly identified variant.

The German and U.S. companies said two doses of their vaccine resulted in significantly lower neutralising antibodies but could still be protective against severe disease.

Read More

Login to be able to comment

Leave a comment